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BRIEF COMMUNICATION
 Of the 712 men originally randomly 
assigned, four had a history of prostate 
cancer, 61 had been randomly assigned to 
aspirin only, and four did not complete any 
study questionnaire, leaving 643 men for 
this analysis ( Figure 1 ). Spearman rank 
correlation coeffi cient was used to cal -
culate the correlation between dietary 
(excluding supplemental) and circulating 
levels of folate (Spearman rho correlation 
coeffi cient = 0.25,  P < .001). We used 
Kaplan – Meier curves and Cox proportional 
hazard models to assess the association 
between folic acid supplementation and 
prostate cancer incidence. Graphical evalu-
ation by Schoenfeld residual plots indicated 
that the model assumptions concerning 
proportional hazards were appropriate ( 18 ). 
We used 1    S ( t ) to estimate absolute risks 
of prostate cancer over defi ned follow-up 
periods, where  S ( t ) is the Kaplan – Meier 
probability of surviving free of prostate 
cancer. All analyses of effects of folic acid 
treatment were conducted according to the 
principle of intention to treat. To analyze 
dietary intake, we computed the residuals 
of the regression of the logarithm of the 
dietary folate on the logarithm of calories 
and used the logarithm of caloric intake to 
adjust for energy intake ( 19 ). Circulating 
 Folate is a major carrier of one-carbon 
groups needed for methylation reactions 
and nucleotide synthesis ( 1 ). Although 
there is currently concern about a possible 
harmful role of folate in colorectal cancer 
( 2 , 3 ), its effects on prostate cancer are not 
clear ( 4 – 12 ). 
 We report here secondary fi ndings 
regarding prostate cancer incidence in the 
context of a double-blind randomized clini-
cal trial of aspirin and/or folic acid for the 
prevention of colorectal adenomas, the 
Aspirin/Folate Polyp Prevention Study 
( 13 ). Patients eligible for the trial had a 
recent history of colorectal adenomas and 
no contraindication, or need, for aspirin or 
folate. A study colonoscopy was scheduled 
3 years after the qualifying examination to 
assess adenoma recurrence. Subsequently, 
subjects were invited to remain in study 
follow-up and to continue the folic acid 
treatment to which they had been randomly 
assigned until the time of an additional 
colonoscopy, which was usually performed 
3 – 5 years after the year 3 examination. 
Informed consent was obtained for each 
participant, and institutional review boards 
at each institution approved the research. 
 At study entry, all participants completed 
a risk factor questionnaire and a semi -
quantitative food frequency questionnaire 
( 14 ); nonfasting blood samples were collec-
ted and used to measure circulating levels of 
folate and other B vitamins. Quality control 
procedures and assay coeffi cients of variation 
(CVs) have been reported elsewhere ( 15 – 17 ). 
For plasma vitamin B 6 , within-day CV and 
between-day CVs were 5.1% – 7.4%; for 
ribofl avin the range was 3.1% – 7.8% ( 15 ). 
 While on study treatment, subjects were 
sent questionnaires every 4 months regarding 
adherence to treatment, use of medications 
and supplements, and medical events. Similar 
questionnaires were sent annually to subjects 
while they were under observational fol-
low-up. Medical records were obtained for 
all patient reports of prostate cancer, and the 
diagnosis was confi rmed by histopathology. 
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levels and dietary intake of folate were 
modeled as continuous variables adjusted 
for potential confounders (age; alcohol use; 
log of caloric intake [dietary only]; baseline 
multivitamin use; dietary intake or plasma 
levels of vitamins B 2 , B 6 , and B 12 ; aspirin 
treatment group; folic acid treatment 
group) as indicated in  Table 1 . All statisti-
cal tests were two-sided. 
 The mean age of men included in the 
secondary analysis was 57.4 (SD = 9.2) 
years; 41 (6.4%) of the 643 men were 
African American. Of the 643 men, 595 
(93%) agreed to follow-up beyond 3 years 
and 472 (73%) continued the assigned folic 
acid (or placebo) treatment. The character-
istics of the men in the two treatment 
groups were similar. We found no statisti-
cally signifi cant differences between pla-
cebo and folic acid treatment groups for 
dietary folate (placebo [mean] = 350, 95% 
CI = 330 to 370 mg/d); folic acid = 337, 
95% CI = 320 to 354 mg/d), plasma folate 
(placebo = 22.7, 95% CI = 20.7 to 24.7 
nmol/L; folic acid = 23.2, 95% CI = 21.1 to 
25.2 nmol/L), and red blood cell folate 
(placebo = 404.1, 95% CI = 388.2 to 420.0 
nmol/L; folic acid = 388.6, 95% CI = 373.6 
to 403.6 nmol/L). However, those ran-
domly assigned to folic acid supplementa-
tion had statistically signifi cantly lower 
baseline plasma vitamin B 12 (placebo = 
348.1 pmol/L; folic acid = 317.0 pmol/L, 
difference = 31.1 pmol/L, 95% CI = 1.8 to 
60.4 pmol/L,  P = .04). 
 A total of 34 subjects were diagnosed 
with prostate cancer after random assign-
ment. Detailed information regarding 
clinical stage was available for only 17 of 
them, but only three cancers were known 
to have spread beyond the capsule. The 
mean Gleason score (available for all 
patients) was 6.4 (SD = 1.1) and did not 
differ between treatment groups. There 
was no statistically signifi cant effect of 
aspirin on risk of prostate cancer, but there 
was a marked increase in risk in subjects 
randomly assigned to folic acid relative to 
those in the placebo group ( Figure 2 , 
 Table 1 ). The estimated probability of 
being diagnosed with prostate cancer in 
the folic acid group was 9.7% (95% CI = 
6.5% to 14.5%) over 10 years and in the 
placebo group it was 3.3% (95% CI = 
1.7% to 6.4%). The age-adjusted hazard 
ratio (HR) was 2.63 (95% CI = 1.23 to 
5.65,  P = .01). 
 In contrast to the direct association of 
folic acid supplementation with risk of 
prostate cancer in the randomized analysis, 
there were possible indications of inverse 
associations of prostate cancer risk with 
dietary folate intake (multiadjusted HR = 
0.65, 95% CI = 0.35 to 1.20), and with 
baseline plasma folate among subjects who 
did not use multivitamins (multiadjusted 
HR = 0.42, 95% CI = 0.17 to 1.04,  Table 1 ). 
Dietary intake of B 2 and B 6 and plasma B 2 , 
B 6 , B 12 was not associated with risk (data 
not shown). 
 The reason for the contrasting associa-
tions of folate supplementation and base-
line intake or circulating levels of folate 
with the risk of prostate cancer is unknown. 
Folate supplementation in the trial was in 
the form of folic acid, a fully oxidized, 
monoglutamyl form of folate that may dif-
fer in its effects from the natural reduced 
and methylated forms (mostly 5-methyl 
tetrahydrofolate). Folic acid is more bio-
available than natural sources ( 20 ); natural 
folates exist as polyglutamates that are 
hydrolyzed to monoglutamates in the 
small intestine and then polyglutamated in 
peri pheral cells ( 21 ). The borderline 
inverse asso ciation of dietary intake and 
plasma levels (among nonmultivitamin 
users) is consistent with some observa-
tional data that natural folates could be 
protective against prostate cancer ( 7 ). 
However, protective dietary associations 
could be confounded by other factors if 
foods rich in folate also contain protective 
nutrients or are associated with protective 
lifestyle habits. 
 There are plausible biological reasons 
why high levels of folate may promote 
carcinogenesis. Folates have a key role in 
the synthesis of nucleotides ( 1 , 2 ) that are 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Some observational studies had suggested 
that increased folate in the diet might lower 
the risk of prostate cancer. 
 Study design 
 This study addressed the effect of folic acid 
supplementation on risk of prostate cancer 
in the context of a double-blind random-
ized clinical trial of folic acid and/or aspirin 
for prevention of colorectal adenoma. 
Dietary intake of folate was assessed at 
baseline. 
 Contribution 
 Folic acid supplementation was associated 
with increased risk of prostate cancer. By 
contrast, baseline dietary folate was 
inversely associated with prostate cancer 
risk. 
 Implications 
 Folate metabolism may have a complex 
role in prostate cancer; the effects of folic 
acid – containing supplements on the risk of 
prostate cancer may be different those of 
natural dietary sources. 
 Limitations 
 Given the small number of prostate cancers 
in this study, the estimates of prostate can-
cer risk in the placebo and folic acid groups 
should be interpreted with caution. 
 From the Editors  
  
 Figure 1 .  Design of the trial and fl ow of participants. 
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needed for proliferating neoplastic cells, 
and there is an increase in the expression of 
folate receptors in several cancer types ( 22 ). 
Prostate-specifi c membrane antigen, a 
transmembrane-carboxypeptidase with 
folate hydrolase activity ( 23 , 24 ), is overex-
pressed in nearly all prostate cancers, and 
higher tissue levels of this protein are asso-
ciated with higher grade, higher Gleason 
score ( 25 ), and disease recurrence ( 26 ). 
Folate also has a key role in DNA methyla-
tion ( 1 , 2 ), and alterations in methylation 
patterns including global DNA hypometh-
ylation ( 27 ) and gene-specifi c hypomethy-
lation ( 28 ) appear to be important events in 
prostate cancer. Unmetabolized folic acid 
has recently been associated with reduced 
natural killer cell cytotoxicity ( 29 ), which 
could impair fi rst-line defense against 
malignant cells ( 30 ). 
 Our study has several limitations. It was 
a secondary analysis, and the estimates of 
risk may not be precise given the small 
number of prostate cancers observed. No 
systematic attempts were made to detect 
early cancers through a protocol-driven 
rectal examination or measurement of 
prostate-specifi c antigen. Therefore, we 
could not control for screening. In addi-
tion, food frequency questionnaires may be 
subject to error. Lastly, most of the subjects 
in our cohort who developed prostate can-
cer had localized tumors with an average 
Gleason score of 6, so we could not inves-
tigate effects on advanced prostate cancer. 
 Strengths of this study include the 
random assignment of folic acid supple-
mentation, which minimized the possibil-
ity of confounding, and its prospective 
design, which minimized recall biases. 
Medical re cords were obtained for all 
subjects who were reported to have devel-
oped prostate cancer, with a blinded 
review to verify dia gnosis and ascertain 
disease characteristics. 
 In conclusion, this clinical trial provides 
evidence that daily supplementation with 
1 mg of folic acid was associated with an in -
creased risk of prostate cancer. It is unclear 
why dietary and plasma levels among non-
multivitamin users may be inversely asso-
ciated with risk. These fi ndings highlight 
the potentially complex role of folate in pro-
 state carcinogenesis. 
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